EUVIMEDEUVIMED entdecken
Open Access

Proteogenomic characterization of pulmonary large-cell neuroendocrine carcinoma identifies molecular features and therapeutic strategy

Lele Zhang iD, Liangdong Sun, Shengnan Duan iD, Yilv Yan, Jinyi Song iD, Linghui Xia iD, Huansha Yu, Jijun Sun iD, Junjie Hu, Di Wang, Lu Han iD, Jue Wang iD und 6 weitere

Science Advances · 14.08.2026 · 12 (33)

DOI: 10.1126/sciadv.adz0583 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Science Advances, erschienen am 14.08.2026. Verfasst von Lele Zhang und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic Surgery, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai 200433, China. Hauptthemen laut MEDLINE: Proteogenomics, Carcinoma, Neuroendocrine, Lung Neoplasms, Carcinoma, Large Cell. Die Arbeit nennt 104 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: National Natural Science Foundation of China, Science and Technology Commission of Shanghai Municipality, Innovation Program of Shanghai Municipal Education Commission.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Pulmonary large-cell neuroendocrine carcinoma (LCNEC) is a rare yet highly aggressive subtype of non-small cell lung carcinoma (NSCLC) with limited therapeutic options. We conduct a comprehensive proteogenomic analysis of LCNEC using tumors and paired normal adjacent tissues from 107 patients (81 pure LCNEC and 26 combined LCNEC). APOBEC mutational signatures strongly correlate processes of tumor initiation and immune suppression, and KEAP1 mutations correlate with metabolic reprogramming in LCNEC combined with NSCLC. A conflicting relationship is observed between neuroendocrine and immune phenotypes. We identify three LCNEC subtypes with unique prognosis features, microenvironment dysregulation, genetic alterations, and potential therapeutic targets. Interleukin-33 (IL-33) emerges as a critical therapeutic biomarker associated with enhanced T cell infiltration and antitumor activity. We further optimize recombinant IL-33 (rIL33) with site-directed mutagenesis and develop PEGylated rIL33, demonstrating its prolonged circulation time in cynomolgus monkeys and superior immune agonist activity in mouse models. Overall, this study offers insights into LCNEC biology and provides promising innovative immunoagonist therapy strategies for lung cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ProteogenomicsCarcinoma, NeuroendocrineLung NeoplasmsCarcinoma, Large CellHumansAnimalsMiceFemaleMaleMutation

Autor:innen und Institutionen

  • Department of Thoracic Surgery, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai 200433, China.
  • Central Laboratory, Innovation and Incubation Center, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai 200433, China.
  • State Key Laboratory of Natural Medicines, School of Life Science and Technology, China Pharmaceutical University, Nanjing 211198, China.
  • Department of Animal Experimental Center, Innovation and Incubation Center, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai 200433, China.
  • Tissue Bank, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai 200433, China.
  • Department of Analytical Chemistry, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China.

ORCID-Profile: Lele Zhang, Shengnan Duan, Jinyi Song, Linghui Xia, Jijun Sun, Lu Han, Jue Wang, Hu Zhou, Chen Wang, Haiyang Hu, Ming Ding, Peng Zhang

Förderung

  • National Natural Science Foundation of China
  • Science and Technology Commission of Shanghai Municipality
  • Innovation Program of Shanghai Municipal Education Commission
  • Shanghai Pulmonary Hospital

Zitieren

APA

Zhang, L., Sun, L., Duan, S., Yan, Y., Song, J., Xia, L., Yu, H., Sun, J., Hu, J., Wang, D., Han, L., Wang, J., Chen, Y., Zhou, H., Wang, C., Hu, H., Ding, M., & Zhang, P. (2026). Proteogenomic characterization of pulmonary large-cell neuroendocrine carcinoma identifies molecular features and therapeutic strategy. Science Advances, 12(33). https://doi.org/10.1126/sciadv.adz0583

Vancouver

Zhang L, Sun L, Duan S, Yan Y, Song J, Xia L, et al. Proteogenomic characterization of pulmonary large-cell neuroendocrine carcinoma identifies molecular features and therapeutic strategy. Science Advances. 2026;12(33). doi:10.1126/sciadv.adz0583

BibTeX
@article{Zhang2026,
  author = {Zhang, Lele and Sun, Liangdong and Duan, Shengnan and Yan, Yilv and Song, Jinyi and Xia, Linghui and Yu, Huansha and Sun, Jijun and Hu, Junjie and Wang, Di and Han, Lu and Wang, Jue and Chen, Yan and Zhou, Hu and Wang, Chen and Hu, Haiyang and Ding, Ming and Zhang, Peng},
  title = {Proteogenomic characterization of pulmonary large-cell neuroendocrine carcinoma identifies molecular features and therapeutic strategy},
  journal = {Science Advances},
  year = {2026},
  volume = {12},
  number = {33},
  doi = {10.1126/sciadv.adz0583}
}
Kostenlos starten →